Previous 10 | Next 10 |
2023-12-08 12:45:17 ET Gainers: Intensity Therapeutics ( INTS ) +100% . MBIA ( MBI ) +74% . Conduit Pharmaceuticals ( CDT ) +47% . EF Hutton Acquisition Corp I ( EFHT ) +44% . Alx Oncology Holdings ( ALXO ) +35% . View ( VI...
2023-12-08 09:00:53 ET More on Veradigm Veradigm: Some Promise Combined With Uncertainty Veradigm announces receipt of Nasdaq delisting notice Veradigm provides audit update and updates financial guidance for 2023 For further details see: Veradigm reshuff...
lululemon athletica inc. (LULU) is expected to report $2.27 for Q3 2024 Arco Platform Limited (ARCE) is expected to report $-0.17 for Q3 2023 Elekta AB ADR (EKTAY) is expected to report for Q2 2024 Kimberly - Clark de Mexico S.A. ADR (KCDMY) is expected to report for Q1 2024 Torri...
SAN FRANCISCO, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Hagens Berman urges Veradigm Inc. (NASDAQ: MDRX) investors who suffered substantial losses to submit your losses now . Class Period: Feb. 26, 2021 – June 13, 2023 Lead Plaintiff Deadline: Jan. 22, 2024 Visit: ...
Faruqi & Faruqi Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Veradigm To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $100,000 investing in Veradigm securities between February 26, 2021 and...
Veradigm Inc. (MDRX) is expected to report $0.17 for Q3 2023 Aperam SA New York Shares (APEMY) is expected to report for Q3 2023 HTG Molecular Diagnostics Inc. (HTGMQ) is expected to report for Q3 2023 Enel Spa ADR (ENLAY) is expected to report for Q3 2023 Firm Capital Property Tr...
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages MDRX Investors with Substantial Losses to Contact Firm San Francisco, California--(Newsfile Corp. - November 29, 2023) - Hagens Berman urges Veradigm Inc. (NASDAQ: MDRX) investors who suffered substantial losses to submit your losses now . ...
Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Veradigm To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Veradigm between February 26, 2021 and June 13, 2023 and would like to discuss your legal rights, c...
SAN FRANCISCO, Nov. 27, 2023 (GLOBE NEWSWIRE) -- Hagens Berman urges Veradigm Inc. (NASDAQ: MDRX) investors who suffered substantial losses to submit your losses now . Class Period: Feb. 26, 2021 – June 13, 2023 Lead Plaintiff Deadline: Jan. 22, 2024 Visit: ...
Boston, Massachusetts--(Newsfile Corp. - November 27, 2023) - A class action lawsuit has been filed against Veradigm, Inc. (NASDAQ: MDRX) for securities law violations. Investors who purchased shares and have lost money are encouraged to contact the firm to learn more about how they might ...
News, Short Squeeze, Breakout and More Instantly...
Allscripts Healthcare Solutions Inc. Company Name:
MDRX Stock Symbol:
NASDAQ Market:
Payer analytics solutions receive top rankings for Client Satisfaction, Reliability, Best of Breed Technology and Process Improvement Veradigm ® (OTCMKTS: MDRX), a leading provider of healthcare data and technology solutions, announced today that Black Book Research ...
For the third consecutive year, the comprehensive set of solutions has been rated the overall #1 provider for small physician practice clearinghouse services Veradigm ® (OTCMKTS: MDRX), a leading provider of healthcare data and technology solutions, announced today that...
Veradigm Inc. (OTCMKTS: MDRX, the "Company”), a leading provider of healthcare data and technology solutions, today announced that it has initiated a process to explore strategic alternatives to maximize shareholder value. As part of the evaluation process, Veradigm will explore pote...